Literature DB >> 21839131

Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Jeremy C Jones1, Erik W Settles, Curtis R Brandt, Stacey Schultz-Cherry.   

Abstract

Given the poor immunogenicity of current H5N1 influenza vaccines, additives and adjuvants remain a viable solution for increasing efficacy. Here, we demonstrate that a 20-amino acid peptide (EB) possessing influenza antiviral activity also enhances the immune response to H5N1 vaccination in mice. The addition of EB to formalin-inactivated whole-virus vaccine induced virion aggregation and these aggregates were readily engulfed by phagocytic cells in vitro. In vivo, mice vaccinated with a suboptimal dose of inactivated vaccine containing EB peptide had reduced morbidity, improved viral clearance, and faster recovery than mice receiving vaccine alone. This phenomenon was not accompanied by an increase in virus-specific antibodies. Instead, cell-mediated immunity was enhanced as demonstrated by increased interferon-γ production from splenocytes. This data demonstrates that the EB peptide may a useful adjuvant for boosting the efficacy of poorly immunogenic influenza vaccines.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839131      PMCID: PMC3190079          DOI: 10.1016/j.vaccine.2011.07.133

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  52 in total

1.  Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Authors:  Jerome P Jayasekera; E Ashley Moseman; Michael C Carroll
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

2.  Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.

Authors:  Xiuhua Lu; Lindsay E Edwards; Julia A Desheva; Doan C Nguyen; Andrey Rekstin; Iain Stephenson; Kristy Szretter; Nancy J Cox; Larisa G Rudenko; Alexander Klimov; Jacqueline M Katz
Journal:  Vaccine       Date:  2006-06-05       Impact factor: 3.641

Review 3.  Neutralization of animal virus infectivity by antibody.

Authors:  S A Reading; N J Dimmock
Journal:  Arch Virol       Date:  2007-02-15       Impact factor: 2.574

4.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Authors:  Isabel Leroux-Roels; Astrid Borkowski; Thomas Vanwolleghem; Mamadou Dramé; Frédéric Clement; Eliane Hons; Jeanne-Marie Devaster; Geert Leroux-Roels
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

5.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Authors:  Jiangtao Lin; Jiansan Zhang; Xiaoping Dong; Hanhua Fang; Jiangting Chen; Nan Su; Qiang Gao; Zhenshan Zhang; Yuxuan Liu; Zhihong Wang; Meng Yang; Ruihua Sun; Changgui Li; Su Lin; Mei Ji; Yan Liu; Xu Wang; John Wood; Zijian Feng; Yu Wang; Weidong Yin
Journal:  Lancet       Date:  2006-09-16       Impact factor: 79.321

6.  Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells.

Authors:  Jeremy C Jones; Elizabeth A Turpin; Hermann Bultmann; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

7.  Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.

Authors:  Ai Ninomiya; Masaki Imai; Masato Tashiro; Takato Odagiri
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

8.  Vaccines for seasonal and pandemic influenza.

Authors:  Kristin L Nichol; John J Treanor
Journal:  J Infect Dis       Date:  2006-11-01       Impact factor: 5.226

9.  Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses.

Authors:  Tesfaldet Tecle; Mitchell R White; Don Gantz; Erika C Crouch; Kevan L Hartshorn
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

10.  Avian influenza H5N1 in tigers and leopards.

Authors:  Juthatip Keawcharoen; Kanisak Oraveerakul; Thijs Kuiken; Ron A M Fouchier; Alongkorn Amonsin; Sunchai Payungporn; Suwanna Noppornpanth; Sumitra Wattanodorn; Apiradee Theambooniers; Rachod Tantilertcharoen; Rattapan Pattanarangsan; Nlin Arya; Parntep Ratanakorn; D M E Osterhaus; Yong Poovorawan
Journal:  Emerg Infect Dis       Date:  2004-12       Impact factor: 6.883

View more
  13 in total

1.  Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Authors:  Brian J Lenny; Stephanie Sonnberg; Angela F Danner; Kimberly Friedman; Richard J Webby; Robert G Webster; Jeremy C Jones
Journal:  Vaccine       Date:  2017-02-08       Impact factor: 3.641

2.  Mapping Murine Corneal Neovascularization and Weight Loss Virulence Determinants in the Herpes Simplex Virus 1 Genome and the Detection of an Epistatic Interaction between the UL and IRS/US Regions.

Authors:  Kyubin Lee; Aaron W Kolb; Inna Larsen; Mark Craven; Curtis R Brandt
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

Review 3.  A Virus Is a Community: Diversity within Negative-Sense RNA Virus Populations.

Authors:  Lavinia J González Aparicio; Carolina B López; Sébastien A Felt
Journal:  Microbiol Mol Biol Rev       Date:  2022-06-23       Impact factor: 13.044

4.  The Entry Blocker Peptide Produced in Chlamydomonas reinhardtii Inhibits Influenza Viral Replication in vitro.

Authors:  Karen Lizbeth Reyes-Barrera; Ruth Elena Soria-Guerra; Rogelio López-Martínez; Leonor Huerta; Nohemí Salinas-Jazmín; Carlos Cabello-Gutiérrez; Ángel Gabriel Alpuche-Solís
Journal:  Front Plant Sci       Date:  2021-05-12       Impact factor: 5.753

5.  Potential of acylated peptides to target the influenza A virus.

Authors:  Daniel Lauster; Damian Pawolski; Julian Storm; Kai Ludwig; Rudolf Volkmer; Henry Memczak; Andreas Herrmann; Sumati Bhatia
Journal:  Beilstein J Org Chem       Date:  2015-04-29       Impact factor: 2.883

6.  Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.

Authors:  Erik A Karlsson; Tomer Hertz; Cydney Johnson; Andrew Mehle; Florian Krammer; Stacey Schultz-Cherry
Journal:  MBio       Date:  2016-08-02       Impact factor: 7.867

7.  The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.

Authors:  Liusong Yin; Xiaoying Chen; Abhinav Tiwari; Paolo Vicini; Timothy P Hickling
Journal:  J Immunol Res       Date:  2015-11-22       Impact factor: 4.818

8.  Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.

Authors:  Han Lei; Sha Jin; Erik Karlsson; Stacey Schultz-Cherry; Kaiming Ye
Journal:  J Immunol Res       Date:  2016-12-19       Impact factor: 4.818

9.  A Perfect Storm: Increased Colonization and Failure of Vaccination Leads to Severe Secondary Bacterial Infection in Influenza Virus-Infected Obese Mice.

Authors:  Erik A Karlsson; Victoria A Meliopoulos; Nicholas C van de Velde; Lee-Ann van de Velde; Beth Mann; Geli Gao; Jason Rosch; Elaine Tuomanen; Jon McCullers; Peter Vogel; Stacey Schultz-Cherry
Journal:  mBio       Date:  2017-09-19       Impact factor: 7.867

Review 10.  Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity.

Authors:  Hussain Badani; Robert F Garry; William C Wimley
Journal:  Biochim Biophys Acta       Date:  2014-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.